Clinical usefulness of bone markers in prostate cancer with bone metastasis

International Journal of Urology

Volumn 19, Issue 11, 2012, Pages 968-979

  Kamiya, Naoto ^a   Suzuki, Hiroyoshi ^a   Endo, Takumi ^a   Yano, Masashi ^a   Naoi, Makito ^a   Nishimi, Daisuke ^a   Kawamura, Koji ^b   Imamoto, Takashi ^b   Ichikawa, Tomohiko ^b  

^a TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Bone marker; Bone metastasis; Prostate cancer; Skeletal relative event

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; BONE SIALOPROTEIN; CABOZANTINIB; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; DASATINIB; DENOSUMAB; DOCETAXEL; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 6; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN; PROCOLLAGEN; PROSTATE SPECIFIC ANTIGEN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SOMATOMEDIN B; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; ZOLEDRONIC ACID;

ADVANCED CANCER; BONE DENSITY; BONE METABOLISM; BONE METASTASIS; BONE REMODELING; BONE TURNOVER; CANCER PROGNOSIS; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG SAFETY; HUMAN; NONHUMAN; OSSIFICATION; OSTEOCLASTOGENESIS; OSTEOLYSIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

BONE AND BONES; BONE NEOPLASMS; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84868204665     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.03098.x     Document Type: Review

References (99)

1. Brown JE, Cook RJ, Major P etal. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl. Cancer Inst. 2005; 97: 59-69.
2. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80: 1588-94.
3. Mittan D, Lee S, Miller E, Perez RC etal. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J. Clin. Endocrinol. Metab. 2002; 87: 3656-61.
4. Daniell HW, Dunn SR, Ferguson DW etal. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J. Urol. 2000; 163: 181-6.
5. Saylor PJ, Kaufman DS, Michaelson MD etal. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J. Urol. 2010; 183: 2200-5.
6. Shahinian VB, Kuo YF, Freeman JL etal. Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 2005; 352: 154-64.
7. Coleman R, Brown J, Terpos E etal. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat. Rev. 2008; 34: 629-39.
8. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 2001; 27: 165-76.
9. Oefelein MG, Ricchiuti V, Conrad W etal. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J. Urol. 2002; 168: 1005-7.
10. Rosenthal DI. Radiologic diagnosis of bone metastases. Cancer 1997; 80: 1595-607.
11. Citrin DL, Bessent RG, Greig WR. A comparison of the sensitivity and accuracy of the 99TCm-phosphate bone scan and skeletal radiograph in the diagnosis of bone metastases. Clin. Radiol. 1997; 28: 107-17.
12. Sabbatini P, Larson SM, Kremer A etal. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J. Clin. Oncol. 1999; 17: 948-57.
13. Corrie D, Timmons JH, Bauman JM etal. Efficacy of follow-up bone scans in carcinoma of the prostate. Cancer 1988; 61: 2453-4.
14. Oesterling JE, Martin SK, Bergstralh EJ etal. The use of prostate specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269: 57-60.
15. Kamiya N, Suzuki H, Endo T etal. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis. Urology 2010; 75: 1446-51.
16. Akimoto S, Furuya Y, Akakura K etal. Inability of bone turnover marker as a strong prognostic indicator in prostate cancer patients with bone metastasis: comparison with the extent of disease (EOD) grade. Prostate 1999; 38: 28-34.
17. Nakashima J, Sumitomo M, Miyajima A etal. The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer. J. Urol. 1997; 157: 1736-9.
18. Ozu C, Nakashima J, Horiguchi Y etal. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. Int. J. Urol. 2008; 15: 419-22.
19. Noguchi M, Noda S. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J. Urol. 2001; 166: 1106-10.
20. Hegele A, Wahl HG, Varga Z etal. Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer. BJU Int. 2007; 99: 330-4.
21. Miyaji Y, Saika T, Yamamoto Y etal. Effects of gonadotropin releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. Urology 2004; 64: 128-31.
22. Majour P. Optimal management of metastatic bone disease. Eur. J. Oncol. Nurs. 2007; 11: 32-7.
23. Berenson JR, Rosen LS, Howell A etal. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. A double-blind, randomized dose-response study. Cancer 2001; 91: 1191-200.
24. Saad F, Gleason DM, Murray R etal. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl. Cancer Inst. 2002; 94: 1458-68.
25. Saad F, Lipton A. Bone-marker levels in patients with prostate cancer: potential correlations with outcomes. Curr. Opin. Support Palliat. Care 2010; 4: 127-34.
26. Lipton A, Jacobs I. Denosumab: benefits of RANK ligand inhibition in cancer patients. Curr. Opin. Support Palliat. Care 2011; 5: 258-64.
27. Scher HI, Halabi S, Tannock I etal. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 2008; 26: 1148-59.
28. Armstrong AJ, Febbo PG. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. Oncologist 2009; 14: 816-27.
29. Armstrong AJ, Garrett-Mayer ES, Yang YC etal. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin. Cancer Res. 2007; 13: 6396-403.
30. Halabi S, Small EJ, Kantoff PW etal. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 2003; 21: 1232-7.
31. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001; 142: 5050-5.
32. Clines GA, Guise TA. Molecular mechanisms and treatment of bone metastasis. Expert Rev. Mol. Med. 2008; 10: e7.
33. Yonou H, Aoyagi Y, Kanomata N etal. Prostate-specific antigen induces osteoplastic changes by an autonomous mechanism. Biochem. Biophys. Res. Commun. 2001; 289: 1082-7.
34. Fohr B, Dunstan CR, Seibel MJ. Clinical review 165: markers of bone remodeling in metastatic bone disease. J. Clin. Endocrinol. Metab. 2003; 88: 5059-75.
35. Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin. Chem. 1999; 45: 1359-68.
36. Moss DW. Diagnostic aspects of alkaline phosphatase and its isoenzymes. Clin. Biochem. 1987; 20: 225-30.
37. Garnero P, Buchs N, Zekri J etal. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br. J. Cancer 2000; 82: 858-64.
38. Gutman EB, Sproul EE, Gutman AB. Significance of increased phosphatase activity of bone at the site of osteoblastic metastases secondary to carcinoma of the prostate gland. Am. J. Cancer 1936; 28: 485-95.
39. Bishop MC, Hardy JG, Taylor MC etal. Bone imaging and serum phosphatases in prostatic carcinoma. Br. J. Urol. 1985; 57: 317-24.
40. Wymenga LF, Boomsma JH, Groenier K etal. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. BJU Int. 2001; 88: 226-30.
41. Hill CS, Wolfert RL. The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clin. Chim. Acta 1989; 186: 315-20.
42. Lorente JA, Valenzuela H, Morote J etal. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. Eur. J. Nucl. Med. 1999; 26: 625-32.
43. European Association of Urology guidelines: prostate cancer. 2012. [Cited 1 Jul 2012.] Available from URL: http://www.uroweb.org/gls/pdf/08%20Prostate%20Cancer_LR%20March%2013th%202012.pdf
44. Delmas PD. Biochemical markers of bone turnover. Theoretical considerations and clinical use in osteoporosis. Am. J. Med. 1993; 95: 11S-16S.
45. Garnero P, Grimaux M, Seguin P etal. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J. Bone Miner. Res. 1994; 9: 255-64.
46. Taylor AK, Linkhart S, Mohan S, Christenson RA, Singer FR, Baylink DJ. Multiple osteocalcin fragments in human urine and serum as detected by a midmolecule osteocalcin radioimmunoassay. J. Clin. Endocrinol. Metab. 1990; 70: 467-72.
47. Delmas PD, Christiansen C, Mann KO etal. Bone Gla protein (osteocalcin) assay standardization report. J. Bone Miner. Res. 1990; 5: 5-11.
48. Masters PW, Jones RG, Purves DA etal. Commercial assays for serum osteocalcin give clinically discordant results. Clin. Chem. 1994; 40: 358-63.
49. Knapen MHJ, Nieuwenhuijzen Kruseman AC, Wouters RS etal. Correlation of serum osteocalcin fractions with bone mineral density in women during the first 10years after menopause. Calcif. Tissue Int. 1998; 63: 375-9.
50. Minisola S, Rosso R, Romagnoli E etal. Serum osteocalcin and bone mineral density at various skeletal sites: a study performed with three different assays. J. Lab. Clin. Med. 1997; 129: 422-9.
51. Ivaska KK, Kakonen S-M, Gerdhem P etal. Urinary osteocalcin as a marker of bone metabolism. Clin. Chem. 2005; 51: 618-28.
52. Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical application of biological markers of bone turnover. Endocr. Rev. 1996; 17: 333-68.
53. Terpos E, Politou M, Rahemtulla A. The role of markers of bone remodeling in multiple myeloma. Blood Rev. 2005; 19: 125-42.
54. Thurairaja R, Iles RK, Jefferson K etal. Serum amino-terminal propeptide of type 1 procollagen (P1NP) in prostate cancer: a potential predictor of bone metastases and prognosticator for disease progression and survival. Urol. Int. 2006; 76: 67-71.
55. Brasso K, Christensen IJ, Johansen JS etal. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 2006; 66: 503-13.
56. Coleman RE. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 2002; 94: 2521-33.
57. Pecherstorfer M, Seibel MJ, Woitge HW etal. Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood 1997; 90: 3743-50.
58. Pectasides D, Farmakis D, Nikolaou M etal. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer. J. Pharm. Biomed. Anal. 2005; 37: 171-6.
59. Shimozuma K, Sonoo H, Fukunaga M etal. Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report. Jpn. J. Clin. Oncol. 1999; 29: 16-22.
60. Jakob C, Zavrski I, Heider U etal. Serum levels of carboxyterminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography. Clin. Cancer Res. 2003; 9: 3047-51.
61. Politou M, Terpos E, Nadal E etal. Prolonged effect of reduced intensity conditioning (RIC) allogeneic transplantation for multiple myeloma on biochemical markers of bone remodeling and osteoclast function: report of a case. Haema 2004; 7: 87-91.
62. Samma S, Kagebayashi Y, Yasukawa M etal. Sequential changes of urinary pyridinoline and deoxypyridinoline as markers of metastatic bone tumor in patients with prostate cancer: a preliminary study. Jpn. J. Clin. Oncol. 1997; 27: 26-30.
63. Takeuchi S, Arai K, Saitoh H etal. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. J. Urol. 1996; 156: 1691-5.
64. Sano M, Kushida K, Takahashi M etal. Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis. Br. J. Cancer 1994; 70: 701-3.
65. Jung K, Lein M, Stephan C etal. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int. J. Cancer 2004; 111: 783-91.
66. Rajpar S, Massard C, Laplanche A etal. Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. Ann. Oncol. 2010; 21: 1864-9.
67. Sassi ML, Eriksen H, Risteli L etal. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 2000; 26: 367-73.
68. Koopmans N, de Jong IJ, Breeuwsma AJ etal. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J. Urol. 2007; 178: 849-53.
69. Koga H, Naito S, Koto S etal. Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer. Prostate 1999; 39: 1-7.
70. Halleen JM. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Anticancer Res. 2003; 23: 1027-9.
71. Halleen JM, Alatalo SL, Janckila AJ etal. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin. Chem. 2001; 47: 597-600.
72. Woitge HW, Pecherstorfer M, Li Y etal. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J. Bone Miner. Res. 1999; 14: 792-801.
73. Brown JM, Corey E, Lee ZD etal. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001; 57: 611-16.
74. Chen G, Sircar K, Aprikian A etal. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006; 107: 289-98.
75. Jung K, Stephan C, Semjonow A etal. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. J. Urol. 2003; 170: 2302-5.
76. Kamiya N, Suzuki H, Endo T etal. Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis. Int. J. Clin. Oncol. 2011; 16: 366-72.
77. Mountzios G, Dimopoulos MA, Bamias A etal. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol. 2007; 46: 221-9.
78. Body JJ, Greipp P, Coleman RE etal. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003; 97: 887-92.
79. Valverde P, Tu Q, Chen J. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically. J. Bone Miner. Res. 2005; 20: 1669-79.
80. Nagata T, Bellows CG, Kasugai S etal. Biosynthesis of bone proteins [SPP-1 (secreted phosphoprotein-1, osteopontin), BSP (bone sialoprotein) and SPARC (osteonectin)] in association with mineralized-tissue formation by fetal-rat calvarial cells in culture. Biochem. J. 1991; 274: 513-20.
81. Fedarko NS, Jain A, Karadag A etal. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin. Cancer Res. 2001; 7: 4060-6.
82. National Comprehensive Cancer Network guideline: prostate cancer. Version 2. 2012. [Cited 1 Jul 2012.] Available from URL: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
83. Saad F, Gleason DM, Murray R etal. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl. Cancer Inst. 2004; 96: 879-82.
84. Rosen LS, Gordon D, Tchekmedyian NS etal. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100: 2613-21.
85. Rosen LS, Gordon D, Kaminski M etal. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 1735-44.
86. Coleman RE, Major P, Lipton A etal. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J. Clin. Oncol. 2005; 23: 4925-35.
87. Saad F, Eastham JA, Smith MR. Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer. Urol. Oncol. 2012; 30: 369-78.
88. Lipton A, Cook R, Saad F. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008; 113: 193-201.
89. Lein M, Wirth M, Miller K etal. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression. Eur. Urol. 2007; 52: 1381-7.
90. Izumi K, Mizokami A, Itai S etal. Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis. BJU Int. 2012; 109: 394-400.
91. Fizazi K, Carducci M, Smith M etal. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-22.
92. Smith MR, Egerdie B, Hernandez Toriz N etal. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 2009; 361: 745-55.
93. Smith MR, Saad F, Egerdie B etal. Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer. J. Bone Miner. Res. 2011; 26: 2827-33.
94. Yu EY, Massard C, Gross ME etal. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 2011; 77: 1166-71.
95. Lombardo LJ, Lee FY, Chen P etal. Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 2004; 47: 6658-61.
96. Yu EY, Wilding G, Posadas E etal. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2009; 15: 7421-8.
97. Araujo JC, Mathew P, Armstrong AJ etal. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer 2012; 118: 63-71.
98. Hussain M, Smith A, Sweeney C etal. Phase II study of XL184 in a cohort of patients with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease. J. Clin. Oncol. 2011; 29 (Suppl 7) Abstract 127.
99. Dayyani F, Gallick GE, Logothetis CJ etal. Novel therapies for metastatic castrate-resistant prostate cancer. J. Natl. Cancer Inst. 2011; 103: 1665-75.